ABBVIE
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 747
- Registration Number
- NCT03345823
- Locations
- 🇺🇸
Baylor Scott & White Center for Inflammatory Bowel Diseases /ID# 170161, Dallas, Texas, United States
🇺🇸Duplicate_Rush University Medical Center /ID# 165470, Chicago, Illinois, United States
🇺🇸University of Washington /ID# 164646, Seattle, Washington, United States
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 526
- Registration Number
- NCT03345849
- Locations
- 🇦🇺
Fiona Stanley Hospital /ID# 171513, Murdoch, Western Australia, Australia
🇺🇸Velocity Clinical Research - Salt Lake City /ID# 166076, West Jordan, Utah, United States
🇺🇸Rush University Medical Center /ID# 165497, Chicago, Illinois, United States
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
- Conditions
- Crohn's Disease
- Interventions
- Drug: Matching Placebo for UpadacitinibDrug: Upadacitinib
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 624
- Registration Number
- NCT03345836
- Locations
- 🇦🇷
Cardio Alem /ID# 211284, San Isidro, Buenos Aires, Argentina
🇺🇸Facey Medical Foundation /ID# 203137, Mission Hills, California, United States
🇺🇸CB Flock Research Corporation /ID# 166220, Mobile, Alabama, United States
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 350
- Registration Number
- NCT03342144
- Locations
- 🇦🇹
Hanusch Krankenhaus /ID# 221151, Wien, Austria
🇩🇪Praxis Dr. Kreher /ID# 202604, Bad Liebenwerda, Brandenburg, Germany
🇩🇪Friedrich-Ebert-Krankenhaus GmbH /ID# 206206, Neumuenster, Schleswig-Holstein, Germany
Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
- Conditions
- Hepatitis C Virus (HCV)
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1095
- Registration Number
- NCT03341871
- Locations
- 🇯🇵
Abbvie Japan /ID# 161985, Tokyo, Japan
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 95
- Registration Number
- NCT03339128
- Locations
- 🇧🇬
MHATSv.Ivan Rilski /ID# 235399, Kozloduy, Bulgaria
🇧🇬University Hospital Plovdiv /ID# 235450, Plovdiv, Bulgaria
🇨🇦Duplicate_Edmonton Clinic Health Academy (ECHA) /ID# 234917, Edmonton, Canada
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
- Conditions
- Non-infectious Intermediate, Posterior and Panuveitis
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 158
- Registration Number
- NCT03339102
- Locations
- 🇰🇷
Yeungnam University Med Ctr /ID# 201361, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷Pusan National University Hosp /ID# 202026, Busan, Busan Gwang Yeogsi, Korea, Republic of
🇰🇷Soon Chun Hyang University Cheonan Hospital /ID# 204551, Cheonan, Chungcheongnamdo, Korea, Republic of
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
- Conditions
- PsoriasisAnkylosing Spondylitis (AS)Rheumatoid Arthritis (RA)
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 224
- Registration Number
- NCT03339089
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital /ID# 210820, Hangzhou, Zhejiang, China
🇨🇳The Second Hospital of Jiaxing /ID# 210744, Jiaxing, Zhejiang, China
🇨🇳Sichuan Provincial orthopedic hospital /ID# 209341, Chengdu, China
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03334487
- Locations
- 🇺🇸
VA Central California Health C /ID# 170951, Fresno, California, United States
🇺🇸St. Luke's University Hospital /ID# 171374, Duluth, Minnesota, United States
🇧🇷Bahia Oncology Center - NOB /ID# 201272, Salvador, Bahia, Brazil
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
- Conditions
- Breast Cancer
- Interventions
- Drug: SC-005
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2
- Registration Number
- NCT03316794
- Locations
- 🇺🇸
Memorial Sloan Kettering /ID# 201016, New York, New York, United States
🇺🇸University of Chicago /ID# 169231, Chicago, Illinois, United States
🇺🇸Washington University School /ID# 169177, Saint Louis, Missouri, United States